Device Changes, FDA Changes, and the 510(K)

John E  Lincoln
Instructor: John E  Lincoln
Date: Monday July 28, 2025
Time:

10:00 AM PDT | 01:00 PM EDT

Duration: 90 Minutes
Webinar Id: 24185

Price Details

Live Webinar
$150. One Attendee
$290. Unlimited Attendees
Recorded Webinar
$190. One Attendee
$390. Unlimited Attendees
Combo Offers   (Live + Recorded)
$289 $340   One Attendee
$599 $680   Unlimited Attendees

Unlimited Attendees: Any number of participants

Recorded Version: Unlimited viewing for 6 months (Access information will be emailed 24 hours after the completion of live webinar)

Overview:

This webinar will provide valuable guidance to regulated companies in development and implementation of formal, defined, documented methods for analysis of product changes and when to file a new 510(k).

Consideration of the U.S. FDA's two current guidance documents, "510(k) Device Modifications: Deciding When to Submit a 510(k) for a [Software} Change to an Existing Device", will provide tools to document such decisions. These analysis must be done for 1) each change, and 2) all cummulative changes collectively, documented

Why you should Attend:

Control of medical device changes and a current 510(k) are big issues in recent FDA studies. Companies are held fully responsible for deciding when a new 510(k) filing is warranted. Often this is a difficult decision process. Effective change control and the power of current risk management tools must be a major part of such an analysis .

The U.S. FDA has published two Guidance Documents, "510(k) Device Modifications: Deciding When to Submit a 510(k) for a Change [and Software Change] to an Existing Device", onOctober 25, 2017, which provide companies tools to perform meaningful, results driven 510(k) / change analysis activities. This is part of a growing push by the Agency to strengthen the 510(k) process. The addition of simple tools, decision trees and questions, will assist companies in implementing formal, documented, repeatable methods with defensible rationale for their decisions on when a new 510(k) submission is required.    

Areas Covered in the Session:

  • Current FDA Expectations
  • Key requirements of the two Guidance Documents on Changes and the 510(k)
  • Expected sources of information for evaluation and inclusion
  • Approaches to the use of the FDA's two Guidance Documents
  • Step-by-step analysis: Manufacturing, Labeling, Tech / Performance, and/or Materials Changes
  • Change reporting "tipping point" - with one change or cumulative
  • Which of the three major 510(k) formats should be used
  • How to complete, document and control as a 'living' document

Who Will Benefit:

  • Senior Management
  • Regulatory Affairs
  • Quality Assurance
  • Production
  • R&D and Engineering
  • All Personnel Tasked with new and Changed Product Development and Documentation

Speaker Profile
John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.

Sign Up for Our Newsletter